Back to search results

Understanding How Germs Evade Our Immune System

This observational study aims to understand how certain germs (pathogenic microorganisms) avoid being destroyed by our body's defense cells, called phagocytes (like white blood cells). Researchers want to identify the specific ways these germs trick our immune system, leading to illness. This study is looking for healthy adults, aged 18 to 120 years old, who do not have any known medical problems. The goal is to learn more about these interactions to better understand diseases and inflammatory conditions. The study is ongoing, and researchers are actively working to identify and describe these evasion mechanisms.

Study design
This is an observational study with a planned enrollment of 200 participants. It does not specify a phase.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for an ongoing period, as the primary endpoint is measured at 'Ongoing'.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00339287

Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens

Recruiting
Not specifiedAges 18+Observational
National Institute of Allergy and Infectious Diseases (NIAID)
~200 participants
Updated 2026-09-16 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
identify and characterize specific mechanisms used by pathogenic microorganisms to evade or subvert normal phagocyte responses and therefore cause disease.
Measured over Ongoing

Conditions

Host Defense Mechanisms

Explore related trials

Healthy Volunteers

NCT00339287

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • NIAID, Rocky Mountain Laboratories

    Hamilton, Montanano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Frank R De Leo, Ph.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)

Who to contact

Frank R De Leo, Ph.D.
[email protected]
(406) 363-9448
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects must fit the definition of "healthy adults" as assessed by the medical/health screening evaluations, and willing to have blood and/or tissue samples stored for future use.
Inasmuch as all subjects are RML employees, they will be 18 years of age or older.
Children are excluded.
Pregnant women will be identified by verbal history and are not eligible to donate blood for this protocol.
The study population will be all-inclusive except in certain instances where individuals possess genetic defects that impair phagocyte function (e.g., myeloperoxidase-deficiency) or have altered phagocyte function due to outside influences such as recent bacterial or viral infection.
Individuals below the normal hematocrit and hemoglobin ranges will be excluded from the protocol.

What this trial measures

  • identify and characterize specific mechanisms used by pathogenic microorganisms to evade or subvert normal phagocyte responses and therefore cause disease.Ongoing

    The study involves the use of human subjects as a source of blood for in vitro assays with bacteria, the isolation of hematopoietic cells (polymorphonuclear leukocytes, mononuclear phagocytes, erythrocytes, and lymphocytes), and serum as a source of complement, antibody, and matrix-binding proteins.